Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Kenjiro Hira

Hitoshi Ban

Naoaki Shimada

Seiji Kamioka

Wataru Hirose

Akihiko Arakawa

Kazuto Yamazaki

The compound of formula (1a) wherein p is 1 or 2, R-Rare hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Optically active azabicyclo ring derivative

The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R-Rare hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin. 

Growing community of inventors

Osaka, Japan

Kenjiro Hira